Ensign Peak Advisors Inc Lowers Holdings in Progyny, Inc. $PGNY

Ensign Peak Advisors Inc lowered its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 9.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,616 shares of the company’s stock after selling 3,350 shares during the period. Ensign Peak Advisors Inc’s holdings in Progyny were worth $718,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Leibman Financial Services Inc. grew its position in shares of Progyny by 1.1% in the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock worth $1,011,000 after buying an additional 513 shares during the last quarter. M&G PLC grew its holdings in Progyny by 2.6% in the second quarter. M&G PLC now owns 30,542 shares of the company’s stock valued at $672,000 after purchasing an additional 764 shares during the period. Polen Capital Management LLC raised its position in Progyny by 0.3% during the first quarter. Polen Capital Management LLC now owns 261,506 shares of the company’s stock worth $5,842,000 after acquiring an additional 798 shares during the period. Cetera Trust Company N.A lifted its stake in Progyny by 303.1% in the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after buying an additional 985 shares in the last quarter. Finally, Militia Capital Partners LP increased its position in shares of Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock worth $45,000 after purchasing an additional 1,000 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PGNY shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. Raymond James Financial set a $28.00 price target on Progyny in a research report on Friday, August 8th. KeyCorp upgraded Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price target on the stock in a research note on Tuesday, November 11th. Finally, Canaccord Genuity Group lifted their price target on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Insider Buying and Selling

In other Progyny news, CEO Peter Anevski purchased 79,500 shares of Progyny stock in a transaction dated Thursday, November 13th. The stock was acquired at an average cost of $24.29 per share, with a total value of $1,931,055.00. Following the acquisition, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at $16,523,296.79. This represents a 13.23% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the transaction, the chief financial officer owned 48,358 shares of the company’s stock, valued at $1,233,129. This represents a 30.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 9.40% of the company’s stock.

Progyny Stock Down 1.2%

PGNY opened at $26.39 on Monday. Progyny, Inc. has a 52 week low of $13.86 and a 52 week high of $27.51. The business’s 50 day moving average is $21.75 and its two-hundred day moving average is $22.14. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 41.88, a price-to-earnings-growth ratio of 2.08 and a beta of 0.96.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The business had revenue of $313.35 million during the quarter, compared to the consensus estimate of $299.23 million. During the same period in the prior year, the company earned $0.11 earnings per share. The company’s revenue was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. Equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.